2 Information about etrasimod

Marketing authorisation indication


Etrasimod (Velsipity, Pfizer) is indicated for 'people 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy, or a biological agent'.

Dosage in the marketing authorisation


The dosage schedule will be available in the summary of product characteristics for etrasimod.



The list price of 2 mg etrasimod is £843.84 per pack of 28 tablets (excluding VAT; company submission). The estimated annual cost of treatment is £11,000 (excluding VAT; company submission).


The company has a commercial arrangement. This makes etrasimod available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.